tetano
Editor, Senior Moderator
Front Biosci (Landmark Ed)
. 2022 Jan 5;27(1):3.
doi: 10.31083/j.fbl2701003.
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines
Evelyn J Franco[SUP] 1 2 [/SUP], Kelly L Warfield[SUP] 3 [/SUP], Ashley N Brown[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: SARS-CoV-2 is the coronavirus responsible for the COVID-19 pandemic. Although it poses a substantial public health threat, antiviral regimens against SARS-CoV-2 remain scarce. Here, we evaluated the antiviral potential of UV-4B, a host targeting antiviral, against SARS-CoV-2 in clinically relevant human cell lines.
Methods: Cells derived from human lung (A549 cells transfected with human angiotensin converting enzyme 2 receptor (ACE2; ACE2-A549)) and colon (Caco-2) were infected with either a wild type or beta variant strain of SARS-CoV-2 and exposed to various concentrations of UV-4B. Supernatant was sampled daily and viral burden was quantified by plaque assay on Vero E6 cells.
Results: Therapeutically feasible concentrations of UV-4B inhibited the replication of the wild type strain in ACE2-A549 and Caco-2 cells yielding EC50 values of 2.694 and 2.489 μM, respectively. UV-4B's antiviral effect was also robust against the beta variant in both cell lines (ACE2-A549 EC50: 4.369 μM; Caco-2 EC50: 6.816 μM).
Conclusions: These results highlight UV-4B's antiviral potential against several strains of SARS-CoV-2.
Keywords: Antiviral; COVID-19; Host targeting; SARS-CoV-2; UV-4B; Variant.
. 2022 Jan 5;27(1):3.
doi: 10.31083/j.fbl2701003.
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines
Evelyn J Franco[SUP] 1 2 [/SUP], Kelly L Warfield[SUP] 3 [/SUP], Ashley N Brown[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35090308
- DOI: 10.31083/j.fbl2701003
Abstract
Background: SARS-CoV-2 is the coronavirus responsible for the COVID-19 pandemic. Although it poses a substantial public health threat, antiviral regimens against SARS-CoV-2 remain scarce. Here, we evaluated the antiviral potential of UV-4B, a host targeting antiviral, against SARS-CoV-2 in clinically relevant human cell lines.
Methods: Cells derived from human lung (A549 cells transfected with human angiotensin converting enzyme 2 receptor (ACE2; ACE2-A549)) and colon (Caco-2) were infected with either a wild type or beta variant strain of SARS-CoV-2 and exposed to various concentrations of UV-4B. Supernatant was sampled daily and viral burden was quantified by plaque assay on Vero E6 cells.
Results: Therapeutically feasible concentrations of UV-4B inhibited the replication of the wild type strain in ACE2-A549 and Caco-2 cells yielding EC50 values of 2.694 and 2.489 μM, respectively. UV-4B's antiviral effect was also robust against the beta variant in both cell lines (ACE2-A549 EC50: 4.369 μM; Caco-2 EC50: 6.816 μM).
Conclusions: These results highlight UV-4B's antiviral potential against several strains of SARS-CoV-2.
Keywords: Antiviral; COVID-19; Host targeting; SARS-CoV-2; UV-4B; Variant.